452P Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): time to maximum response and optimal treatment duration.
Authors
Lamarca, AngelaBarriuso, Jorge
McCallum, Lynne
Papaxoinis, Georgios
Nasralla, Magdy
Nuttall, Christina
Frizziero, Melissa
Kordatou, Zoe
McNamara, Mairéad G
Hubner, Richard A
Manoharan, Prakash
Mansoor, Was
Valle, Juan W
Affiliation
Medical Oncology, The Christie NHS Foundation Trust, ManchesterIssue Date
2017-09
Metadata
Show full item recordCitation
452P Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): time to maximum response and optimal treatment duration. 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx368.024Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx368.024/4108673/452PTemozolomidecapecitabine-TemCap-chemotherapyType
Meetings and ProceedingsLanguage
en_USISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx368.024